Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-12-18 | New | $13,505,000 | $13,505,000 | Equity and Debt | 06b | SEC link |
| 2023-10-11 | New | $2,399,629 | $2,399,629 | Equity and Debt | 06b | SEC link |
| 2023-08-31 | New | $1,900,000 | $1,900,000 | Equity Only | 06b | SEC link |
| 2023-02-08 | New | $13,000,000 | $13,000,000 | Debt Only | 06b | SEC link |
| 2022-03-24 | New | $12,999,991 | $12,999,991 | Equity Only | 06b | SEC link |
| 2021-04-20 | New | $3,000,000 | $3,000,000 | Equity and Debt | 06b | SEC link |
| 2021-03-22 | New | $5,000,515 | $5,000,515 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Thomas Bumol, Ph D | Director |
| Frank Cammisa, Md | Director |
| Jason Gallagher | Executive |
| Fran Magee | Executive |
| Marc R. Viscogliosi | Director, Executive |
| John J. Viscogliosi | Director |
| Llc Viscogliosi Brothers, | Executive |